In some people who carry a repeat expansion in the C9ORF72 gene, methylation of the gene promoter shuts down its transcription. This offers a modicum of protection against amyotrophic lateral ...
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that ...
SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Hosted on MSN
Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab
Alector Inc. (NASDAQ:ALEC) is one of the best stocks under $3 to invest in. On October 21, Alector announced the topline results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001 ...
As the frontotemporal lobar degeneration field approaches an era of prevention and clinical trials, it needs robust biomarkers that herald the onset of symptoms and track the progression of a person’s ...
Side-by-side image shows control neurons from the study (left) compared to neurons from the study with the mis-spliced KCNQ2 gene. Protein TDP-43 malfunctions and disrupts the normal splicing of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results